BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--PEAR Therapeutics, the leader in prescription digital therapeutics, today announced that Corey McCann, M.D., Ph.D., President and CEO of PEAR Therapeutics, will present a company update at the annual BIO CEO & Investor Conference taking place on Tuesday, February 13, 2018, at the New York Marriott Marquis in New York. The company also will participate in the LEERINK Partners 7th Annual Global Healthcare Conference taking place February 14-15, 2018, at the Lotte New York Palace Hotel in New York.
PEAR Therapeutics is a privately-held company developing clinically validated, FDA-cleared prescription digital therapeutics to treat severe medical conditions. Recently, the company received FDA clearance for reSET® to treat substance abuse disorder and an Expedited Access Pathway designation from the FDA for reSET-O™ to treat Opioid Use Disorder.
About PEAR Therapeutics
PEAR Therapeutics is the leader in FDA-cleared prescription digital therapeutics. The company’s approach is to integrate clinically-validated software applications with previously approved pharmaceuticals and treatment paradigms to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. PEAR’s lead product, reSET®, is an FDA-cleared 12-week interval prescription therapeutic for Substance Use Disorder (SUD) to be used as an adjunct to standard, outpatient treatment. PEAR’s product development pipeline includes reSET-O™ for opioid use disorder (OUD) and additional prescription digital therapeutics in schizophrenia (THRIVE™), combat post-traumatic stress disorder (reCALL™), general anxiety disorder (reVIVE™), pain, major depressive order, and insomnia, for which PEAR intends to obtain FDA clearance. For more details, please see www.peartherapeutics.com.